BioSpace News Archive

$52 million is being allocated to progress IND-enabling studies in adrenomyeloneuropathy (AMN) and grow the pipeline in rare, monogenic neurological diseases

NiKang is eligible to receive an upfront collaboration fee and milestone payments of more than $100 million plus royalties on future net product sales

Spectrum Pharmaceuticals a biopharmaceutical company focused on novel and targeted oncology therapies, announced the appointment of Seth H.Z. Fischer to its Board of Directors.

Lead pneumococcal vaccine currently in clinical trials designed to provide broadest protection

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced that it will release financial results for the first quarter ended March 31, 2020 before the market open on Monday, May 4, 2020.

Idera Pharmaceuticals, Inc. announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 agonist, will be presented at the American Association for Cancer Research Virtual Annual Meeting I, to be held April 27-28, 2020, as part of a “Clinical Trial Poster Session.”.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that it has received approval from the Ministry of Food and Drug Safety in South Korea, as well as ethics approval, for an investigator-led, Phase 2 COVID-19 clinical study of its re-purposed drug NP-120 (Ifenprodil), an NMDA receptor antagonist. Th

Proceeds enable advancement of lead program into clinical development and support progression of additional programs

QIAGEN N.V. announced that it plans to release its report on results for the first quarter 2020 results on Wednesday, May 6, at approximately 22:05 Central European Time / 16:05 Eastern Day Time..

Menlo Therapeutics Inc. announced that its wholly-owned subsidiary, Foamix Pharmaceuticals Ltd., has entered into a licensing agreement with specialty pharmaceutical company Cutia Therapeutics Limited, an affiliate of Cutia Therapeutics for AMZEEQ™ topical foam, 4% as well as its other topical minocycline product candidates, once approved, on an exclusive basis in Greater China.